BLTE
BELITE BIO, INC
NASDAQ · Healthcare · Biotechnology · US
$170.96
+0.36%Sep 10, 2026, 01:45 UTC
Belite Bio CFO and Director Chuang Hao-Yuan sold 62,395 American depositary shares for approximately $12.8 million on September 4 and September 8, 2026, under a Rule 10b5-1 trading plan.
Source:Sep 8, 2026, 10:00 UTC
Belite Bio submitted a New Drug Application to Japan's Ministry of Health, Labour and Welfare under the Sakigake designation system for tinlarebant to treat Stargardt disease type 1.
Source:Aug 21, 2026, 12:00 UTC
Belite Bio announced that its data will be presented at two upcoming medical conferences in August 2026.
Source:Aug 11, 2026, 20:01 UTC
The U.S. Food and Drug Administration accepted and granted Priority Review designation to Belite Bio's New Drug Application for tinlarebant for the treatment of Stargardt Disease Type 1, with a PDUFA date set for February 12, 2027.
Aug 6, 2026, 12:00 UTC
Belite Bio announced it will host a webcast on August 13, 2026, to discuss its second quarter 2026 financial results and provide a business update.
Jun 13, 2026, 01:30 UTC
Belite Bio completed its rolling submission of a New Drug Application to the U.S. Food and Drug Administration for tinlarebant for the treatment of Stargardt disease type 1.